Jiangsu Boxin Pharmaceutical Technology Co., Ltd.

To study whether there are differences in the extent and rate of absorption between the test preparation Selexipag tablets (Jiangsu Boxin Pharmaceutical Technology Co., Ltd., specification: 0.2 mg) and the reference preparation Selexipag tablets (trade name: Utopi®, specification: 0.2 mg) after a single oral administration on an empty stomach or after a meal in healthy subjects, to evaluate the bioequivalence of the test preparation and the reference preparation when administered on an empty stomach or after a meal, and to observe the safety of the test preparation and the reference preparation in healthy subjects.

To investigate whether there are differences in the extent and speed of absorption of the test preparation Selexipag tablets (Jiangsu Boxin Pharmaceutical Technology Co., Ltd., specification: 0.2 mg) and the reference preparation Selexipag tablets (trade name: Utopi ®, specification: 0.2 mg) taken orally on an empty stomach or after a meal in healthy subjects, to evaluate the bioequivalence of the test preparation and the reference preparation when administered on an empty stomach or after a meal, and to observe the safety of the test preparation and the reference preparation in healthy subjects